查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1510459

护理点分子诊断市场 - 全球产业规模、份额、趋势、机会和预测，按技术、应用、测试地点、最终用户、地区和竞争细分，2019-2029F

Point-Of-Care Molecular Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Test Location, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年，全球床边分子诊断市场估值为 20.7 亿美元，到 2029 年，预测期内将以 10.93% 的复合年增长率强劲增长。或附近进行的测试，可在短时间内提供快速且可操作的结果。这些测试利用分子技术来检测和分析与特定病原体、遗传变异或疾病生物标记相关的核酸（DNA 或 RNA）。 POC 分子诊断提供快速检测能力，与传统的实验室方法相比，可以在几分钟到几小时内提供结果，而传统的实验室方法可能需要几天才能得出结果。这种快速的周转时间使医疗保健提供者能够立即做出治疗决策、优化患者管理并更有效地实施感染控制措施。 POC 分子诊断利用聚合酶炼式反应(PCR)、核酸扩增测试(NAAT)、环介导等温扩增(LAMP) 和基于CRISPR 的检测等分子技术，以高灵敏度和特异性扩增和检测目标核酸序列。这些技术能够检测与各种疾病和病症相关的病原体、基因突变和生物标记。许多 POC 分子诊断设备被设计为样本到答案平台，将样本製备、核酸萃取、扩增和检测步骤整合到单一仪器或试剂盒中。这些整合平台简化了测试过程，最大限度地减少了动手时间，并降低了污染风险，使其非常适合在实验室基础设施和技术专业知识有限的护理点环境中使用。

市场概况
预测期 2025-2029
2023 年市场规模 20.7亿美元
2029 年市场规模 38.7亿美元
2024-2029 年复合年增长率 10. 93%
成长最快的细分市场 基于杂交的技术
最大的市场 北美洲

分子生物学、微流体和核酸扩增技术的进步促进了高灵敏度、特异性和用户友好的即时分子诊断设备的开发。这些技术创新扩展了即时检测的能力，并提高了诊断结果的准确性和可靠性。由于快速获得诊断服务的需求，尤其是在服务不足或偏远地区，分散检测和即时诊断已成为全球趋势。即时分子诊断消除了对集中实验室设施的需求，并且可以在患者的床边、诊所、急诊室和社区环境中进行测试。护理点分子诊断通常在几分钟到几小时内提供快速测试结果，以便能够及时做出诊断和治疗决策。能够在护理点立即获得结果对于管理传染病、优化患者护理和降低疾病传播风险特别有价值。

主要市场驱动因素

分子诊断技术的进步

越来越多地转向分散测试

对个人化医疗的需求不断增长

主要市场挑战

品质控制和保证

基础设施和连通性

主要市场趋势

小型化、便携化

细分市场洞察

技术洞察

应用洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球护理点分子诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术（基于 PCR、基于基因定序、基于杂交、基于微阵列）
    • 按应用（传染病、肿瘤学、血液学、产前检测、内分泌学、其他）
    • 按测试地点（OTC、POC）
    • 按最终使用者（分散实验室、医院、家庭护理、辅助生活医疗设施、其他）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图

第 6 章：北美护理点分子诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按申请
    • 按考试地点
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲护理点分子诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按申请
    • 按考试地点
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区护理点分子诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按申请
    • 按考试地点
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲护理点分子诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按申请
    • 按考试地点
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲护理点分子诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依技术
    • 按申请
    • 按考试地点
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球护理点分子诊断市场：SWOT 分析

第14章：竞争格局

  • Siemens Healthineers AG
  • Quidel Corporation
  • F. Hoffman-La Roche Ltd.
  • Danaher Corporation
  • Beckton & Dickinson Company
  • Trinity Biotech plc
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • DiaSorin SpA
  • AccuBioTech Co., Ltd

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 23762

Global Point-Of-Care Molecular Diagnostics Market was valued at USD 2.07 billion in 2023 and will see an robust growth in the forecast period at a CAGR of 10.93% through 2029. Point-of-care molecular diagnostics (POC MDx) refers to diagnostic tests that are performed at or near the site of patient care, providing rapid and actionable results within a short timeframe. These tests utilize molecular techniques to detect and analyze nucleic acids (DNA or RNA) associated with specific pathogens, genetic variations, or biomarkers of disease. POC molecular diagnostics offer rapid testing capabilities, providing results in minutes to hours compared to traditional laboratory-based methods, which may take days to deliver results. This rapid turnaround time enables healthcare providers to make immediate treatment decisions, optimize patient management, and implement infection control measures more effectively. POC molecular diagnostics leverage molecular techniques such as polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), loop-mediated isothermal amplification (LAMP), and CRISPR-based assays to amplify and detect target nucleic acid sequences with high sensitivity and specificity. These techniques enable the detection of pathogens, genetic mutations, and biomarkers associated with various diseases and conditions. Many POC molecular diagnostic devices are designed as sample-to-answer platforms, integrating sample preparation, nucleic acid extraction, amplification, and detection steps into a single instrument or cartridge. These integrated platforms streamline the testing process, minimize hands-on time, and reduce the risk of contamination, making them ideal for use in point-of-care settings with limited laboratory infrastructure and technical expertise.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 2.07 Billion
Market Size 2029USD 3.87 Billion
CAGR 2024-202910. 93%
Fastest Growing SegmentHybridization-Based Technology
Largest MarketNorth America

Advances in molecular biology, microfluidics, and nucleic acid amplification technologies have led to the development of highly sensitive, specific, and user-friendly point-of-care molecular diagnostic devices. These technological innovations expand the capabilities of point-of-care testing and improve the accuracy and reliability of diagnostic results. There is a global trend towards decentralized testing and point-of-care diagnostics, driven by the need for rapid access to diagnostic services, especially in underserved or remote areas. Point-of-care molecular diagnostics eliminates the need for centralized laboratory facilities and enable testing to be performed at the patient's bedside, in clinics, emergency departments, and community settings. Point-of-care molecular diagnostics offer rapid test results, often within minutes to hours, enabling timely diagnosis and treatment decisions. The ability to obtain immediate results at the point of care is particularly valuable for managing infectious diseases, optimizing patient care, and reducing the risk of disease transmission.

Key Market Drivers

Advancements in Molecular Diagnostic Technologies

Next-generation sequencing technologies have transformed genomic analysis by enabling high-throughput sequencing of DNA and RNA molecules. NGS platforms offer unparalleled sequencing depth, resolution, and scalability, facilitating a wide range of applications such as whole-genome sequencing, targeted gene sequencing, transcriptomics, and metagenomics. Digital PCR technologies enable precise quantification of nucleic acid targets by partitioning DNA or RNA samples into thousands of individual reactions. Digital PCR offers superior sensitivity, accuracy, and reproducibility compared to conventional PCR methods, making it ideal for detecting rare mutations, measuring gene expression levels, and quantifying viral load in clinical samples. Isothermal amplification techniques, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), allow rapid amplification of nucleic acids at a constant temperature without the need for thermal cycling. These isothermal amplification methods are well-suited for point-of-care diagnostics, field testing, and resource-limited settings due to their simplicity, speed, and robustness.

CRISPR-based diagnostic technologies leverage the CRISPR-Cas system for nucleic acid detection and gene editing. CRISPR-based diagnostics offer rapid and specific detection of target sequences with high sensitivity and specificity, enabling applications such as pathogen detection, genotyping, and mutation analysis. CRISPR-based diagnostics hold promise for point-of-care testing and precision medicine. Microfluidic-based diagnostic platforms integrate microscale fluid handling and analytical techniques for performing complex molecular assays in miniaturized devices. Microfluidic systems offer advantages such as reduced sample volumes, rapid reaction kinetics, and automation capabilities, making them suitable for point-of-care diagnostics, high-throughput screening, and multiplexed assays.

Biosensors and nanotechnology-based platforms enable label-free detection and quantification of biomolecules with high sensitivity and specificity. Biosensors utilize various transduction mechanisms, including optical, electrochemical, and mechanical signals, for real-time and multiplexed detection of nucleic acids, proteins, and small molecules. Nanotechnology enhances the performance of biosensors by providing nanomaterials with unique properties such as enhanced surface area, biocompatibility, and signal amplification. Artificial intelligence (AI) algorithms and machine learning techniques are increasingly applied to analyze large-scale molecular data generated from diagnostic tests, omics studies, and clinical trials. AI-driven data analytics enable rapid interpretation of complex molecular profiles, prediction of disease outcomes, identification of therapeutic targets, and personalized treatment recommendations, thereby improving patient care and clinical decision-making. This factor will help in the development of the Global Point-Of-Care Molecular Diagnostics Market.

Increasing Shift Towards Decentralized Testing

POC molecular diagnostics offer the advantage of providing rapid test results, often within minutes to hours, compared to traditional laboratory-based testing methods that may take days to deliver results. Timely diagnosis enables healthcare providers to make prompt treatment decisions, leading to improved patient outcomes, particularly in acute conditions such as infectious diseases. POC molecular diagnostics bring diagnostic testing directly to the patient's bedside, clinic, or community setting, eliminating the need for samples to be sent to centralized laboratories. This accessibility and convenience reduce the time and logistical barriers associated with traditional laboratory testing, particularly in remote or resource-limited areas where access to centralized healthcare facilities may be limited. By bypassing the need for sample transportation and centralized laboratory processing, POC molecular diagnostics offer significantly reduced turnaround times for test results. This rapid turnaround time is crucial for managing infectious disease outbreaks, implementing timely interventions, and reducing the risk of disease transmission in healthcare settings and communities.

POC molecular diagnostics empower healthcare providers to make informed treatment decisions at the point of care, based on real-time diagnostic information. This immediate feedback loop enhances clinical decision-making, enables targeted therapy, and supports precision medicine approaches tailored to individual patient needs and disease characteristics. POC molecular diagnostics facilitate rapid screening, diagnosis, and monitoring of infectious diseases, chronic conditions, and therapeutic responses. By providing actionable diagnostic information at the point of care, POC molecular diagnostics enable more proactive and personalized patient management strategies, leading to better disease management and treatment outcomes. POC molecular diagnostics play a critical role in public health preparedness and emergency response efforts, particularly during pandemics, outbreaks, and natural disasters. These diagnostics enable rapid screening, surveillance, and containment of infectious diseases, helping to identify and isolate cases, track transmission chains, and inform public health interventions in real time. This factor will pace up the demand of the Global Point-Of-Care Molecular Diagnostics Market.

Growing Demand for Personalized Medicine

Personalized medicine aims to customize medical care and treatment plans based on individual patient characteristics, including genetic makeup, biomarker profiles, and disease susceptibility. POC molecular diagnostics provide rapid and accurate identification of genetic variations, biomarkers, and therapeutic targets, enabling healthcare providers to tailor treatment approaches to each patient's specific needs and disease characteristics. POC molecular diagnostics enable rapid genetic testing and risk assessment for a wide range of conditions, including genetic disorders, hereditary diseases, and cancer predisposition syndromes. By detecting genetic mutations, single nucleotide polymorphisms (SNPs), and other genetic markers at the point of care, POC molecular diagnostics empower patients and healthcare providers to make informed decisions about disease prevention, screening, and management. Pharmacogenomic testing using POC molecular diagnostics helps predict individual responses to medications and optimize drug therapy regimens based on genetic factors. By identifying genetic variations that influence drug metabolism, efficacy, and toxicity, POC molecular diagnostics enable personalized prescribing practices, minimize adverse drug reactions, and enhance treatment outcomes for patients.

POC molecular diagnostics serve as companion diagnostic tests for targeted therapies and precision medicine approaches. These tests help identify patients who are most likely to benefit from specific therapies, such as targeted cancer treatments or immunotherapies, based on their molecular profiles and biomarker expression patterns. POC companion diagnostics enable timely treatment decisions, improve treatment response rates, and reduce the risk of adverse events associated with inappropriate therapy. POC molecular diagnostics facilitate real-time monitoring of disease progression, treatment response, and disease recurrence by measuring biomarker levels and genetic changes over time. By providing actionable diagnostic information at the point of care, POC molecular diagnostics support ongoing disease management strategies, enable early detection of treatment failure or disease relapse, and facilitate adjustments to treatment plans as needed. POC molecular diagnostics empower patients to take an active role in their healthcare decisions by providing access to personalized diagnostic information and treatment options. By involving patients in the decision-making process and tailoring treatment plans to their individual needs and preferences, POC molecular diagnostics enhance patient engagement, satisfaction, and adherence to therapy regimens. This factor will acceleate the demand of the Global Point-Of-Care Molecular Diagnostics Market.

Key Market Challenges

Quality Control and Assurance

POC molecular diagnostic tests are often performed in diverse settings, including clinics, physician offices, pharmacies, and remote locations with limited infrastructure. The variability in testing conditions, such as temperature, humidity, and operator skill level, can affect test performance and result accuracy. Unlike centralized laboratory testing, which is subject to stringent regulatory oversight and quality assurance protocols, POC molecular diagnostics may have less regulatory scrutiny and standardized quality control measures. This lack of uniformity in regulatory requirements and quality standards can lead to variability in test performance and result reliability across different POC testing platforms and devices. POC molecular diagnostic tests rely on high-quality sample collection and handling procedures to ensure accurate and reliable results. However, factors such as sample degradation, contamination, improper storage, and transportation can compromise sample integrity and affect test performance. Maintaining sample quality and stability is challenging in resource-limited or point-of-care settings where access to laboratory facilities and trained personnel may be limited. Developing robust molecular diagnostic assays for POC testing requires extensive optimization and validation to ensure analytical sensitivity, specificity, and reproducibility across diverse sample types and testing conditions. However, assay optimization and validation processes can be time-consuming, labor-intensive, and resource-intensive, posing challenges for manufacturers and developers of POC molecular diagnostic tests.

Infrastructure and Connectivity

POC molecular diagnostics are often deployed in settings where access to centralized laboratory facilities is limited or unavailable. This includes remote rural areas, underserved communities, and regions with inadequate healthcare infrastructure. The lack of laboratory infrastructure hinders the implementation and adoption of POC molecular diagnostic technologies. Many POC testing environments, such as clinics, field hospitals, and mobile healthcare units, operate in resource-limited settings with constrained financial, logistical, and technical resources. These settings may lack basic infrastructure such as reliable electricity, running water, and temperature-controlled storage, which are essential for performing molecular diagnostic tests safely and accurately. POC molecular diagnostic devices often require stable power sources to operate effectively. In regions with unreliable electricity grids or limited access to electricity, maintaining consistent power supply poses a significant challenge. Additionally, battery-operated devices may require frequent recharging or replacement, which can be impractical in resource-constrained settings. POC molecular diagnostic devices may rely on internet connectivity for data transmission, remote monitoring, and result reporting. However, internet infrastructure and connectivity can be unreliable or nonexistent in remote or rural areas, hindering real-time data exchange and communication between POC testing sites and healthcare facilities.

Key Market Trends

Miniaturization and Portability

Miniaturization and portability make molecular diagnostic technologies more accessible to a wider range of settings, including remote and resource-limited areas where access to centralized laboratory facilities may be limited or nonexistent. Portable POC devices can be deployed in clinics, field hospitals, community health centers, and even mobile healthcare units, bringing diagnostic testing closer to patients and improving healthcare access and equity. Miniaturized POC molecular diagnostic devices offer rapid testing capabilities, allowing for on-the-spot diagnosis and timely treatment decisions. With shorter turnaround times compared to traditional laboratory-based testing methods, portable POC devices enable healthcare providers to make real-time decisions about patient care, infection control, and public health interventions, particularly during outbreaks and emergencies. Miniaturized POC molecular diagnostic devices are designed for use at the point of care, where patients receive medical attention and treatment. These devices eliminate the need for sample transportation, centralized laboratory processing, and lengthy turnaround times associated with traditional testing methods, improving patient satisfaction, reducing healthcare costs, and enhancing overall workflow efficiency in point-of-care settings. Many miniaturized POC molecular diagnostic devices are compatible with mobile devices such as smartphones and tablets, enabling wireless connectivity, data transfer, and result reporting. Mobile integration allows healthcare providers to access and analyze diagnostic data in real time, track patient outcomes, and collaborate with colleagues remotely, enhancing clinical decision-making and care coordination.

Segmental Insights

Technology Insights

The Hybridization-Based segment is projected to experience rapid growth in the Global Point-Of-Care Molecular Diagnostics Market during the forecast period. Hybridization-based molecular diagnostic assays, such as nucleic acid hybridization and DNA microarrays, offer high sensitivity and specificity for the detection of nucleic acid targets. These assays enable the accurate identification and quantification of target sequences, making them suitable for a wide range of applications, including infectious disease diagnosis, genetic testing, and oncology. Hybridization-based assays support multiplexing, allowing simultaneous detection of multiple targets within a single reaction. This capability is particularly advantageous for diagnosing infectious diseases caused by multiple pathogens or identifying genetic mutations associated with complex diseases. Multiplex assays improve workflow efficiency, conserve sample volume, and reduce turnaround times in point-of-care settings. Hybridization-based assays are versatile and adaptable to different target molecules, including DNA, RNA, and proteins. They can be customized and optimized for specific applications and target sequences, making them suitable for diverse clinical and research purposes. Hybridization-based assays can also be integrated with various detection platforms, including microfluidic devices, biosensors, and portable instrumentation, enhancing their utility in point-of-care settings.

Application Insights

The Oncology segment is projected to experience rapid growth in the Global Point-Of-Care Molecular Diagnostics Market during the forecast period. There has been a significant rise in the incidence of cancer globally. Molecular diagnostics play a crucial role in cancer detection, prognosis, and treatment selection, which has driven the demand for point-of-care molecular diagnostic tools specifically designed for oncology applications. Timely and accurate diagnosis is critical for effective cancer treatment. Point-of-care molecular diagnostics offer the advantage of quick and precise testing at or near the patient, enabling faster diagnosis and treatment initiation. This is especially crucial in oncology, where early detection can significantly improve patient outcomes. There is a growing trend towards personalized medicine in oncology, where treatment decisions are tailored to individual patients based on their molecular profile. Point-of-care molecular diagnostics facilitate this approach by enabling real-time testing and immediate adjustment of treatment plans based on molecular findings.

Regional Insights

North America emerged as the dominant region in the Global Point-Of-Care Molecular Diagnostics Market in 2023. North America possesses advanced healthcare infrastructure, featuring well-established laboratory facilities, robust healthcare systems, and stringent regulatory frameworks. This infrastructure facilitates the development, validation, and adoption of point-of-care molecular diagnostics within the region. Renowned for its technological innovation, North America hosts numerous leading companies and research institutions actively engaged in advancing molecular diagnostic technologies. These entities drive growth in the point-of-care molecular diagnostics market by pioneering breakthroughs in molecular biology, microfluidics, and sensor technologies. North America serves as a focal point for significant investments in research and development (R&D) for healthcare technologies, particularly point-of-care molecular diagnostics. Funding from diverse sources, including government agencies, private investors, and venture capital firms, propels innovation and expedites the commercialization of new diagnostic products and platforms.

Key Market Players

Siemens Healthineers AG

Quidel Corporation

F. Hoffman-La Roche Ltd.

Danaher Corporation

Beckton & Dickinson Company

Trinity Biotech plc

Thermo Fisher Scientific Inc

bioMerieux S.A.

DiaSorin S.p.A

AccuBioTech Co., Ltd.

Report Scope:

In this report, the Global Point-Of-Care Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-Of-Care Molecular Diagnostics Market, By Technology:

    PCR-based Genetic Sequencing-based Hybridization-based Microarray-based

Point-Of-Care Molecular Diagnostics Market, By Application:

    Infectious Diseases Oncology Hematology Prenatal Testing Endocrinology Other

Point-Of-Care Molecular Diagnostics Market, By Test Location:

    OTC POC

Point-Of-Care Molecular Diagnostics Market, By End User:

    Decentralized Labs Hospitals Home-care Assisted Living Healthcare Facilities Others

Point-Of-Care Molecular Diagnostics Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-Of-Care Molecular Diagnostics Market.

Available Customizations:

Global Point-Of-Care Molecular Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-Of-Care Molecular Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based)
    • 5.2.2. By Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other)
    • 5.2.3. By Test Location (OTC, POC)
    • 5.2.4. By End User (Decentralized Labs, Hospitals, Home-care, Assisted Living Healthcare Facilities, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map

6. North America Point-Of-Care Molecular Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Test Location
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Test Location
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Test Location
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Test Location
        • 6.3.3.2.4. By End User

7. Europe Point-Of-Care Molecular Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Test Location
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Test Location
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Test Location
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Test Location
        • 7.3.3.2.4. By End User
    • 7.3.4. France Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Test Location
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Test Location
        • 7.3.5.2.4. By End User

8. Asia-Pacific Point-Of-Care Molecular Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Test Location
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Test Location
        • 8.3.1.2.4. By End User
    • 8.3.2. India Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Test Location
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Test Location
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Test Location
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Test Location
        • 8.3.5.2.4. By End User

9. South America Point-Of-Care Molecular Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Test Location
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Test Location
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Test Location
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Test Location
        • 9.3.3.2.4. By End User

10. Middle East and Africa Point-Of-Care Molecular Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Test Location
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Test Location
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Test Location
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Test Location
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Point-Of-Care Molecular Diagnostics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Siemens Healthineers AG
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Service Offerings
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel
    • 14.1.7. SWOT Analysis
  • 14.2. Quidel Corporation
  • 14.3. F. Hoffman-La Roche Ltd.
  • 14.4. Danaher Corporation
  • 14.5. Beckton & Dickinson Company
  • 14.6. Trinity Biotech plc
  • 14.7. Thermo Fisher Scientific Inc
  • 14.8. bioMerieux S.A.
  • 14.9. DiaSorin S.p.A
  • 14.10.AccuBioTech Co., Ltd

15. Strategic Recommendations

16. About Us & Disclaimer